Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.71 |
| ▸ | MAPT | P10636 | 8/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | GRM6 | O15303 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135598 | 0.86 | ALDH1A1 (0.75) | ALDH1A1MAPTLMNAGAAADORA1 | |
| SCHEMBL18551034 | 0.83 | MAPT (0.71) | ALDH1A1MAPTLMNAGAAADORA1 | |
| SCHEMBL881267 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPTLMNAGAAADORA1 | |
| SCHEMBL20280436 | 0.83 | ALDH1A1 (0.71) | ALDH1A1MAPTLMNAGAAADORA1 | |
| SCHEMBL1638729 | 0.83 | ALDH1A1 (1.00) | ALDH1A1MAPTLMNAGAAADORA1 | |
| SCHEMBL7490234 | 0.82 | MAPT (0.69) | ALDH1A1MAPTLMNAGAAADORA1 | |
| SCHEMBL3777726 | 0.81 | ALDH1A1 (0.68) | ALDH1A1MAPTLMNAGAAADORA1 | |
| SCHEMBL1497810 | 0.81 | TDP1 (0.48) | ALDH1A1MAPTLMNAGAAADORA1 | |
| SCHEMBL30893849 | 0.81 | ALDH1A1 (0.68) | ALDH1A1MAPTLMNAGAAADORA1 | |
| SCHEMBL3768717 | 0.81 | CNR2 (0.54) | ALDH1A1MAPTLMNAGAAADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085738-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250130239-A1 | PROTEIN DEGRADER | UNIVERSITY OF DUNDEE (GB) | 2025-04-24 | — | — | US | disclosed |
| WO-2025076236-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025076181-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025076219-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| EP-4405472-A1 | PROTEIN DEGRADER | University of Dundee (GB) | 2024-07-31 | — | — | EP | disclosed |
| CN-118019844-A | Protein degradation agent | 敦提大学 | 2024-05-10 | — | — | CN | disclosed |
| CN-112543764-B | Amide compound with BET proteolytic induction effect and medical application thereof | 田边三菱制药株式会社 | 2024-05-10 | — | — | CN | disclosed |
| CN-110914280-B | 6H-thieno [2,3-e ] [1,2,4] triazolo [3,4-c ] [1,2,4] triazab derivatives | 阿尤米制药公司 | 2024-05-03 | — | — | CN | disclosed |
| US-6323214-B1 | CARDIOVASCULAR DISORDERS, NERVOUS SYSTEM DISORDERS AND ANALGESICS | MEDCO RESEARCH, INC | 2001-11-27 | — | — | US | disclosed |
| US-6194449-B1 | ADMINISTERING A BENZOYLTHIOPHENE COMPOUND; ANTIHYPOXIC, ANTIISCHEMIC AGENTS | MEDCO CORP. | 2001-02-27 | — | — | US | disclosed |
| US-6177444-B1 | ANTIISCHEMIC AGENTS; ANTIARRHYTHMIA AGENTS | MEDCO CORP. | 2001-01-23 | — | — | US | disclosed |
| EP-1025106-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | Medco Research, Inc. (US) | 2000-08-09 | — | — | EP | disclosed |
| US-5939432-A | Thiophenes useful for modulating the adenosine receptor | MEDCO RESEARCH, INC. (US) | 1999-08-17 | — | — | US | disclosed |
| EP-0934940-A1 | CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF | Japan Tobacco Inc. (JP) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999021617-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | MEDCO RESEARCH, INC. (US) | 1999-05-06 | — | — | WO | disclosed |
| US-5807850-A | Therapeutic agent for osteoporosis and triazepine compound | JAPAN TOBACCO, INC. (JP) | 1998-09-15 | — | — | US | disclosed |
| US-5747486-A | ANTIINFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES (JP) | 1998-05-05 | — | — | US | disclosed |
| EP-0792880-A1 | OSTEOPOROSIS REMEDY AND TRIAZEPINE COMPOUND | Japan Tobacco Inc. (JP) | 1997-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | VHL, BRCA1, TP53 | ALDH1A1 246/4885MAPT 2496/4885LMNA 4114/4885 |
| US-20250130239-A1 | PROTEIN DEGRADER | BRD4, BRD1, BRD2 | ALDH1A1 4556/4885MAPT 1087/4885LMNA 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.